Español (España) Búsqueda

Liposome-mediated delivery of a ruthenium-based metallodrug to overcome cisplatin resistance in osteosarcoma

267564

12/08/2026 9:51:17

Murillo D, Domínguez-Jurado E, Huergo C, Gallego B, Díez P, Ferreras A, Álvarez-González E, Rey V, Rodríguez-Santamaría M, Indurain AS, de Andrés Segura F, Bravo I, Ríos Á

https://web.unican.es/ibbtec/es-es/Lists/Papers/AllItems.aspx

False

553

2026-12-30T23:00:00Z

<h2>Abstract</h2>The treatment of osteosarcoma has remained largely unchanged over the past decades. Its low incidence, predominantly affecting children and young adults, combined with marked biological heterogeneity, poses major challenges to the development of effective therapies, and currently approved regimens often yield variable responses. Additionally, the frequent emergence of drug-resistant phenotypes in these mesenchymal tumors further compromises treatment success. As a result, despite substantial research efforts, patients with osteosarcoma still face a poor prognosis, underscoring the urgent need for improved therapeutic strategies. Alongside doxorubicin and methotrexate, cisplatin is one of the primary first-line chemotherapeutic agents used for osteosarcoma. However, like other cytotoxic drugs, cisplatin is limited by severe systemic toxicity and the development of resistance. In this study, we investigated the antitumor potential of a novel ruthenium organometallic compound, Ru3, and its liposomal encapsulation as a nanomedicine approach to provide a safer and more effective alternative to platinum-based therapy for both cisplatin-resistant and parental osteosarcoma models. In vitro, both free and liposomal Ru3 displayed stronger cytotoxicity than cisplatin in most models, effectively reversing drug resistance. Ru3 formulations also maintained potent activity in 3D osteosarcoma spheroids and selectively targeted cancer stem cell-enriched tumorspheres. In vivo, treatment with liposomal Ru3 in mice bearing cisplatin-resistant xenografts produced superior therapeutic outcomes and was better tolerated than cisplatin, alleviating its systemic toxicity. Overall, these findings support ruthenium-based metallodrugs delivered via liposomes as promising alternatives to platinum-based chemotherapy for osteosarcoma management. Keywords: Osteosarcoma; cisplatin; drug-resistance; liposomes; nanoencapsulation; ruthenium.

Murillo D, Domínguez-Jurado E, Huergo C, Gallego B, Díez P, Ferreras A, Álvarez-González E, Rey V, Rodríguez-Santamaría M, Indurain AS, de Andrés Segura F, Bravo I, Ríos Á, Fernández-Velasco AA, Fernández-Vega I, Alonso-Moreno C, Rodríguez R.

IBBTEC17_Paper

Conferencia Especial Fin de Programación

6122

24/08/2026 10:43:43

El IBBTEC cierra el calendario de seminarios de 2026 con una conferencia especial que creemos que os va a sorprender INFORMACIÓN PRÁCTICA Fecha: jueves, 17 de diciembre de

https://web.unican.es/ibbtec/es-es/Lists/Events/AllItems.aspx

False

225

2026-12-16T23:00:00Z

El IBBTEC cierra el calendario de seminarios de 2026 con una conferencia especial que creemos que os va a sorprender.¡Esperamos que asistáis todos! INFORMACIÓN PRÁCTICA Fecha: jueves, 17 de diciembre de 2026 Hora: 12 h. Lugar: Salón de Actos del IBBTEC (Santander - PCTCAN)

Seminario

Pronto se anunciará el ponente

IBBTEC17_Event

Defensa de tesis

103695

28/08/2026 8:15:30

https://web.unican.es/ibbtec/es-es/Lists/Events/AllItems.aspx

False

228

2026-10-08T22:00:00Z

Defensa de tesis. Sandra Moreu Sobera.

Seminario

Sandra Moreu Sobera

IBBTEC17_Event

Defensa de tesis - Estudio del papel de arid2 en el cáncer de pulmón utilizando modelos animales

6200

24/08/2026 10:41:00

David Martín Gutiérrez , investigador del IBBTEC en el laboratorio de Ignacio Varela, defenderá su tesis Estudio del papel de arid2 en el cáncer de pulmón utilizando modelos

https://web.unican.es/ibbtec/es-es/Lists/Events/AllItems.aspx

False

226

2026-10-06T22:00:00Z

David Martín Gutiérrez, investigador del IBBTEC en el laboratorio de Ignacio Varela, defenderá su tesis Estudio del papel de arid2 en el cáncer de pulmón utilizando modelos animales.INFORMACIÓN Tesis: Estudio del papel de arid2 en el cáncer de pulmón utilizando modelos animales. Doctorando: David Martín Gutiérrez. Director: Dr. Ignacio Varela Egocheaga. Programa: Biología Molecular y Biomedicina. Fecha: miércoles, 7 de octubre de 2026. Hora: por determinar. Lugar: Salón de Actos del IBBTEC - Santander - PCTCAN.

Seminario

David Martín Gutiérrez

IBBTEC17_Event

Progress Report

6121

08/09/2026 6:36:47

Progress Repor t by Sara Valero : New Therapeutic Targets in Triple Negative Breast Cancer Directors: Berta Casar and Juan Carlos Acosta The sessions are held weekly in the IBBTEC

https://web.unican.es/ibbtec/es-es/Lists/Events/AllItems.aspx

False

224

2026-09-29T22:00:00Z

Progress Report by Sara Valero: New Therapeutic Targets in Triple Negative Breast Cancer.& Progress Report by Patricia Carrancio.Directors: Berta Casar and Juan Carlos Acosta. Host: Lara Zorro. Wednesday, September 30, - 13 p.m. - IBBTEC Lecture Hall The IBBTEC Progress Reports are a series of research seminars in which young researchers from IBBTEC and IDIVAL present the current status of their projects. The sessions are held weekly in the IBBTEC auditorium and are conducted in English.The series is coordinated by IBBTEC researcher Ramón Merino.

Seminario

Sara Valero and Patricia Carrancio

IBBTEC17_Event

PhD Seminar: Distinct functions of SWI/SNF subunits in shaping tumor cell plasticity and progression in NSCLC

275479

04/09/2026 12:23:53

By: Raquel Marqueño (Ignario Varela's Lab) Wednesday, September 23 - 2026 12 - 14 h Lecture Hall (IBBTEC - PCTCAN - Santander

https://web.unican.es/ibbtec/es-es/Lists/Events/AllItems.aspx

False

229

2026-09-22T22:00:00Z

PhD Seminar: Distinct functions of SWI/SNF subunits in shaping tumor cell plasticity and progression in NSCLC. By: Raquel Marqueño (Ignario Varela's Lab) Wednesday, September 23 - 2026 12 - 14 h Lecture Hall (IBBTEC - PCTCAN - Santander)

Seminario

Raquel Marqueño

IBBTEC17_Event

Seminar: Development of synthetic cells (SimCells) to treat AMR pathogens and cancers.

270222

07/09/2026 11:45:26

Guest speaker: Wei E. Huang (University of Oxford Tuesday, September 22 - 2026 - 12 p.m. IBBTEC Lecture Hall - PCTCAN - Santander - Spain Professor Wei Huang is a

https://web.unican.es/ibbtec/es-es/Lists/Events/AllItems.aspx

False

227

2026-09-21T22:00:00Z

Seminar: Development of synthetic cells (SimCells) to treat AMR pathogens and cancers. Guest speaker: Wei E. Huang (University of Oxford). Host: Matxalen Llosa. Tuesday, September 22 - 2026 - 12 p.m. IBBTEC Lecture Hall - PCTCAN - Santander - Spain Professor Wei Huang is a Biological Engineering faculty member. His research focuses on artificial biological intelligence (ABI), synthetic biology, and single-cell biology. This talk is part of IBBTEC’s year-round seminar programme, coordinated by Juan Carlos Acosta within the framework of the CSIC’s Deep MaX Scientific Excellence Initiative. The IBBTEC is a joint centre of the University of Cantabria and the Spanish National Research Council (CSIC). Its activities are supported by the Spanish Ministry of Science, Innovation and Universities; the European Union through the FEDER, NextGenerationEU and ERC funds; and the Government of Cantabria through the Programme Contract with the University of Cantabria.

Seminario

Wei E. Huang

IBBTEC17_Event

Progress Report

6119

24/08/2026 8:45:41

Progress Report by Andrea Fernández Gómez Hosts: Patricia Carrancio and Natalia García-Tomsig Wednesday, September 16, - 13 p.m. - IBBTEC Lecture Hall The IBBTEC Progress

https://web.unican.es/ibbtec/es-es/Lists/Events/AllItems.aspx

False

222

2026-09-15T22:00:00Z

Progress Report by Andrea Fernández Gómez. Director: Matxalen Llosa. Hosts: Patricia Carrancio and Natalia García-Tomsig. Wednesday, September 16, - 13 p.m. - IBBTEC Lecture Hall The IBBTEC Progress Reports are a series of research seminars in which young researchers from IBBTEC and IDIVAL present the current status of their projects. The sessions are held weekly in the IBBTEC auditorium and are conducted in English.The series is coordinated by IBBTEC researcher Ramón Merino.

Seminario

Andrea Fernández Gómez

IBBTEC17_Event

Progress Report: Harnessing immune-potentiating cancer-associated fibroblast (CAF) subsets for improved breast cancer diagnosis and treatment.

6118

07/09/2026 9:50:52

Wednesday, September 9, - 13 p.m. - IBBTEC Lecture Hall The IBBTEC Progress Reports are a series of research seminars in which young researchers from IBBTEC and IDIVAL present

https://web.unican.es/ibbtec/es-es/Lists/Events/AllItems.aspx

False

221

2026-09-08T22:00:00Z

Progress Report: Harnessing immune-potentiating cancer-associated fibroblast (CAF) subsets for improved breast cancer diagnosis and treatment. By: Sofía Zdral Noguero. Director: Fernando Calvo. Host: Iván Méndez. Wednesday, September 9, - 13 p.m. - IBBTEC Lecture HallThe IBBTEC Progress Reports are a series of research seminars in which young researchers from IBBTEC and IDIVAL present the current status of their projects. The sessions are held weekly in the IBBTEC auditorium and are conducted in English. The series is coordinated by IBBTEC researcher Ramón Merino.

Seminario

Sofía Zdral Noguero

IBBTEC17_Event

Mechanisms and functional implications of long-range enhancer-dependent gene regulation

275231

01/09/2026 9:07:01

Abstract Metazoan development relies on the coordinated establishment of diverse gene regulatory programs that drive the formation of specific cell types, tissues and organs

https://web.unican.es/ibbtec/es-es/Lists/Papers/AllItems.aspx

False

597

2026-08-31T22:00:00Z

<h2>Abstract</h2>Metazoan development relies on the coordinated establishment of diverse gene regulatory programs that drive the formation of specific cell types, tissues and organs. The temporal and spatial control of gene expression is achieved through the concerted activity of multiple classes of cis-regulatory elements encoded in the genome. Among these, enhancers enable the establishment of specific and precise gene expression patterns and control gene expression over long linear distances, a property often referred to as distance-independent regulatory activity. However, enhancer activity is, in fact, inversely correlated with linear genomic distance, and target gene expression and transcriptional precision decrease with increasing enhancer–promoter linear distances. Here, we highlight emerging insights into multiple mechanisms that enable enhancers to precisely and robustly activate gene expression across large genomic distances. Finally, we provide a more speculative perspective on the potential advantages that long-range regulation might confer during the establishment of developmental gene expression programs. doi: <a href="https://doi.org/10.1038/s41588-026-02721-9" target="_blank">https://doi.org/10.1038/s41588-026-02721-9</a>

Iliadou, M., Haro, E. & Rada-Iglesias, A.

IBBTEC17_Paper

IBBTEC

Instituto de Biomedicina y Biotecnología de Cantabria.
PCTCAN - Cl. Albert Einstein, 22
39011 Santander
ibbtec@unican.es

Inicio de sesión

Sobre nosotros

Eventos

Contacto

Login

About us

Events

Contact

Login

IBBTEC